{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:41:30Z","timestamp":1779234090033,"version":"3.51.4"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Blue-light aminolevulinic acid photodynamic therapy (ALA-PDT) after broad-area application and 3-hour incubation is efficacious for actinic keratosis (AK) lesion clearance on upper extremities, with use of occlusive dressing significantly increasing efficacy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To prove the safety and efficacy of ALA-PDT versus vehicle (VEH-PDT) in the spot treatment of multiple AKs on upper extremities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>Aminolevulinic acid or VEH was spot applied only to lesions on one upper extremity 3 hours before blue-light exposure. Treated extremity was covered with occlusive dressing during incubation. Identical treatment was repeated at Week 8 if AK lesions were present in the treated area.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Thirty-one percent (42\/135) of subjects treated with ALA-PDT had complete clearance at Week 12, compared with 13% (17\/134) of the subjects treated with VEH-PDT (<jats:italic toggle=\"yes\">p<\/jats:italic> = .0001). The mean AK lesion clearance rate for ALA-treated subjects at Weeks 8 and 12 was 53% and 69%, respectively, compared with 26% and 30% for the VEH-treated group (<jats:italic toggle=\"yes\">p<\/jats:italic> &lt; .0001, linear mixed model). Safety profile observed in this study is consistent with previous studies\/reports in the literature, and the therapy was well tolerated overall.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Aminolevulinic acid-PDT spot treatment using a 3-hour occluded incubation was superior to VEH-PDT for AK lesion clearance of the upper extremity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000001760","type":"journal-article","created":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T08:53:59Z","timestamp":1547888039000},"page":"890-897","source":"Crossref","is-referenced-by-count":16,"title":["A Randomized, Vehicle-Controlled Phase 3 Study of Aminolevulinic Acid Photodynamic Therapy for the Treatment of Actinic Keratoses on the Upper Extremities"],"prefix":"10.1097","volume":"45","author":[{"given":"Shang I.","family":"Brian Jiang","sequence":"first","affiliation":[{"name":"Mohs and Dermatologic Surgery, University of California, San Diego, San Diego, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kempers","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Minnesota Clinical Study Center, University of Minnesota, Fridley, Minnesota;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phoebe","family":"Rich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Dermatology and Research Center, Oregon Health and Science University, Portland, Oregon;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Marcus","sequence":"additional","affiliation":[{"name":"DUSA Pharmaceuticals, Inc., Wilmington, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Houlihan","sequence":"additional","affiliation":[{"name":"Clinical Research, DUSA Pharmaceuticals, Inc., Wilmington, Massachusetts;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Piacquadio","sequence":"additional","affiliation":[{"name":"Therapeutics, Inc., San Diego, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pariser","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Eastern Virginia Medical School, Virginia Clinical Research, Inc., Norfolk, Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","article-title":"Actinic keratoses: natural history and risk of malignant transformation in the veterans affairs topical tretinoin chemoprevention trial","volume":"116","author":"Criscione","year":"2009","journal-title":"Cancer"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.1073\/pnas.93.24.14025","article-title":"Frequent clones of p53-mutated keratinocytes in normal human skin","volume":"93","author":"Jonason","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"R3-20230816","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/jid.2010.302","article-title":"Sun-induced nonsynonymous p53 mutations are extensively accumulated and tolerated in normal appearing human skin","volume":"131","author":"Stahl","year":"2011","journal-title":"J Invest Dermatol"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archderm.140.1.41","article-title":"Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials","volume":"140","author":"Piacquadio","year":"2004","journal-title":"Arch Dermatol"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1365-2133.2006.07520.x","article-title":"Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up","volume":"155","author":"Tschen","year":"2006","journal-title":"Br J Dermatol"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000246376","article-title":"Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study","volume":"192","author":"Szeimies","year":"1996","journal-title":"Dermatology"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.1997.03890420065007","article-title":"Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid: a pilot dose-ranging study","volume":"133","author":"Jeffes","year":"1997","journal-title":"Arch Dermatol"},{"issue":"3 Pt 1","key":"R9-20230816","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0190-9622(99)70114-3","article-title":"A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses","volume":"41","author":"Kurwa","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1468-3083.2009.03259.x","article-title":"Intraindividual left-right comparison of topical 5-aminolevulinic acid and photodynamic therapy vs 5% imiquimod cream for actinic keratoses on the upper extremities","volume":"23","author":"Sotiriou","year":"2009","journal-title":"J Eur Acad Derm Venereol"},{"key":"R11-20230816","first-page":"1049","article-title":"A randomized, blinded, bilateral intraindividual, vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities","volume":"10","author":"Taub","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"R12-20230816","first-page":"1483","article-title":"A multicenter, randomized, vehicle-controlled phase 2 study of blue light photodynamic therapy with aminolevulinic acid HCl 20% topical solution for the treatment of actinic keratoses on the upper extremities: the effect of occlusion during the drug incubation period","volume":"11","author":"Schmieder","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"R13-20230816","first-page":"1124","article-title":"Effect of retinoid pretreatment on outcomes of patients treated by photodynamic therapy for actinic keratosis of the hand and forearm","volume":"10","author":"Galitzer","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-3758(01)00077-5","article-title":"Optimally weighted, fixed sequence and gatekeeper multiple testing procedures","volume":"99","author":"Westfall","year":"2001","journal-title":"J Stat Plann Inference"},{"key":"R15-20230816","first-page":"1261","article-title":"Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinico-histopathologic correlation","volume":"32","author":"Ehrig","year":"2006","journal-title":"Dermatol Surg"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00042728-201907000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T02:13:52Z","timestamp":1692152032000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042728-201907000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000001760","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}